Futura Medical plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alex Duggan
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Surrey Technology Centre Guildford United Kingdom GU2 7YG
- IPO Date
- May 15, 2012
- Website
- futuramedical.com
- Similar Companies
- Business
- Futura Medical plc Futura Medical plc is a UK-based pharmaceutical research and development company that develops and commercializes clinically proven topical gel formulations for sexual health; its lead product is Eroxon, an over-the-counter topical gel treatment for erectile dysfunction that achieves erections within 10 minutes and is available without prescription in markets including Europe, the US, Middle East, and Latin America; the pipeline includes Eroxon Intense, an enhanced formulation for stronger sensation targeting men preferring greater effect, and WSD4000, a topical treatment addressing symptoms of impaired sexual response and function in women such as lack of desire, arousal, and lubrication, with no known regulatory-approved OTC competitor globally. Founded in 2001 and headquartered at Surrey Technology Centre in Guildford, UK, the company operates a de-risked go-to-market model partnering with major consumer healthcare firms including Haleon plc Haleon plc for US distribution under an IP license agreement generating royalties and milestones, and Cooper Consumer Health for direct sales model launches across multiple European countries; additional partners include Labatec for Middle East markets and M8 Pharmaceuticals in Mexico. Eroxon has expanded to 25 countries since initial 2023 launches in UK and Belgium, with US market entry in October 2024 via Haleon, though HY2025 results reflect slower consumer uptake and repeat sales prompting revised FY2025 revenue guidance to £1.3-1.4 million, inventory provisions, asset impairments, and cash runway into January 2026 pending IP milestone and financing; strategic responses include a comprehensive cost-cutting program, ongoing business review considering asset sales, alternative partnering or licensing for pipeline products, and leadership transition with Alex Duggan appointed interim CEO in August 2025 following departures of prior executives, while Eroxon Intense targets EU/US regulatory approvals by end-2025 and WSD4000 advances toward Q1 2026 FDA feasibility study results.
Futura Medical plc (FAMDF) Q4 2025 Earnings Call Transcript
Microsoft Q3 results top expectations, driven by Intelligent Cloud strength
Futura Medical refines strategy and evolves commercial model after tough 2025
Futura Medical refines strategy and evolves commercial model after tough 2025
Gold just had one of its worst weeks in 40 years. Is it time to buy the dip?
Futura Medical reports positive trial results for upgraded erectile dysfunction gel
Futura Medical reports positive trial results for upgraded erectile dysfunction gel
Nike North America sales growth and inventory reset support turnaround: analysts
Nasdaq set to lead decline as Alphabet spending plans spook investors
Nasdaq drags major indexes lower as Alphabet spending plans spook investors
Qualcomm: A tough start to 2026 in prospect after Q4 earnings beat
Futura secures US patent protection for Eroxon and women's sexual health product
Futura secures US patent protection for Eroxon and women’s sexual health product
Super Micro Computer shares jump on Q2 results, upbeat outlook
Futura Medical shares climb on upbeat revenue forecast and cash position
Futura Medical shares climb on upbeat revenue forecast and cash position
Futura Medical lifts full-year revenue forecast ahead of strategic review
Analysts look to 'cyclicals' as inflexion point approaches
Nasdaq, S&P 500 higher as investors brush off Fed independence concerns, gold surges
US bank urges investors to look beyond the calm... and into small and mid-caps